Focused Antibiotics
Funds United Kingdom and global teams redesigning antibiotic strategies while preserving gut microbiome health.
Wellcome Leap's Focused Antibiotics program is a $50 million initiative targeting one of medicine's most stubborn tradeoffs: antibiotics that kill the target pathogen also devastate the gut microbiome, causing collateral harm that contributes to long-term health consequences. The program challenges performer teams to reformulate existing antibiotics to spare the gut microbiome without sacrificing …
Reformulation of existing antibiotics targeting urinary tract infections, lower respiratory tract infections, and acute otitis media to eliminate gut microbiome collateral damage while maintaining treatment efficacy.
Sign up free to see the funding breakdown
Sign up free to see the industries in scope
Sign up free to see the full eligibility
Sign up free to see how to apply
Sign up free to see what you submit
Sign up free to see the timeline
Guides for this application
All guides →Grants for Biotech Startups: NIH, NSF, SBIR/STTR, and Non-Dilutive Funding
A practical guide to grants for biotech startups, including NIH SBIR/STTR, NSF, translational funding, evidence, regulatory readiness, and budgets.
DocumentsGrant Work Plan Template: Work Packages, Gantt, Milestones, and Risks
Use this grant work plan template to structure work packages, tasks, owners, deliverables, Gantt timing, dependencies, and risk registers.
Submit & reportGrant Reporting Requirements: Post-Award Reports and Compliance
Learn what grant reporting requirements cover, how financial and performance reports work, what to track after an award, and how to avoid post-award compliance mistakes.
Write proposalGrant Concept Note Example: Pre-Proposal Structure for Startups
See a practical grant concept note example, with a worked deeptech pre-proposal, section map, invite-to-full logic, and reviewer checks.
More from Wellcome Leap
All grants from this funder →1kD — Execution
Wellcome Leap · United States
Funds United Kingdom infant brain development research programs focused on translational collaboration.
CARE — Execution
Wellcome Leap · United States
Supports United Kingdom efforts to understand endocrine factors in cognitive aging and dementia risk.
Delta Tissue — Execution
Wellcome Leap · United States
Funds United Kingdom tissue profiling research for improved diagnostics and disease state understanding.
Dynamic Resilience — Execution
Wellcome Leap · United States
Funds healthspan-oriented research in the United Kingdom toward resilient aging and wellness strategies.
FORM
Wellcome Leap · United States
Funds United Kingdom maternal and infant microbiome research to improve long-term health outcomes.
HOPE — Execution
Wellcome Leap · United States
Supports United Kingdom human organ engineering collaborations focused on translational tissue platforms.
Similar grants
Browse the directory →
Improved Drug Susceptibility Testing (DST) for Mycobacteria
NIH · United States
Funds faster drug-susceptibility tests for tuberculosis and related mycobacterial infections that skip slow culture-based methods.
NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention
🇺🇸NIH · United States
Funds stroke trials and biomarker studies run inside NIH's national StrokeNet — with its coordinating centres doing recruitment and data.
ASPIRE Reduction-to-Practice (Seed)
🇺🇸NCATS · United States
Supports translational chemistry and automation platform development through university-linked partnerships.
CARE for Health — Open Funding (Seed)
🇺🇸NIH Common Fund · United States
Supports integrating clinical research into primary care environments through rural-focused network models.
Complement-ARIE — Open Funding (Seed)
🇺🇸NIH Common Fund · United States
Supports development of human-based new approach methodologies replacing animal models in relevant research.
First in Human and Early Stage Clinical Trials of Novel Investigational Drugs or Neuromodulatory Device-based Interventions for Psychiatric Disorders
🇺🇸NIH · United States
Funds the first human trials of a novel-mechanism psychiatric drug or a novel neuromodulatory device, with milestones gating each step.